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patients with Crohn's disease, in the UK, was used; assumptions were made for the health state of complications following surgery.
Measure of benefit:
The measure of benefit was quality-adjusted life-years (QALYs). Discounting was applied at an annual rate of 3.5%.
Cost data:
The direct medical costs included infliximab acquisition and administration, concomitant medications, hospitalisations, and other direct costs. The estimates were from published studies of patients with Crohn's disease, the National Schedule of Reference Costs, and an expert Delphi panel of UK gastroenterologists. They were discounted at 3.5% and reported in UK pounds sterling (£) for the price year 2006 to 2007. Inflationary adjustments were made using the annual UK Health Price Index.
Analysis of uncertainty:
One-way sensitivity analyses were undertaken on the key parameters, and two scenarios tested the assumptions around infliximab efficacy. Probabilistic sensitivity analysis was undertaken, with beta distributions assigned to the health utilities and transition probabilities, and normal distributions assigned to the costs. Ten thousand Monte Carlo simulations were performed and 95% confidence intervals were generated. The results were presented in costeffectiveness acceptability curves (CEACs).
Results
For paediatric patients with severe Crohn's disease, the mean cost per patient, over five years, was £34,012 with infliximab compared with £25,987 with standard care. In the scenario in which no treatment effect was assumed beyond 54 weeks, the mean cost per patient was £31,010 with infliximab and £25,987 with standard care, and in the scenario using only REACH efficacy data (the only data for children), it was £37,181 with infliximab, and £23,186 with standard care.
In the base case, the mean QALYs were 3.224 for infliximab, and 2.675 for standard care. In the two scenarios, the mean QALYs per patient were 2.943 with infliximab and 2.675 with standard care, where no treatment effect was assumed beyond 54 weeks, and 3.468 with infliximab and 3.090 with standard care, where only REACH data were used.
The incremental cost per QALY gained with infliximab over standard care was £14,607. Based on the CEAC, there was a 78.6% likelihood that the incremental cost per QALY gained would be below £30,000, the accepted UK willingnessto-pay threshold. The results were most sensitive to variations in the efficacy of standard care, resulting in an incremental cost per QALY gained of £37,017, using data from REACH only.
